Covid-19 Global Rheumatology Alliance Registry, Anti-Il-6 Therapy, Shared Decision-Making and Patient Outcomes. Response To: 'Correspondence on 'Characteristics Associated with Hospitalisation for Covid-19 in People with Rheumatic Disease: Data from the Covid-19 Global Rheumatology Alliance Physician-Reported Registry' by Gianfrancesco Et Al. Compassionate Use of Tocilizumab in Severe Covid-19 with Hyperinflammation Prior to Advent of Clinical Trials - a Real-World District General Hospital Experience' by Khan Et Al, 'Comment on 'Characteristics Associated with Hospitalisation for Covid-19 in People with Rheumatic Disease: Data from the Covid-19 Global Rheumatology Alliance Physician-Reported Registry' by Gianfrancesco M Et Al' by Andreica Et Al and 'Covid-19 Outcomes in Patients with Systemic Autoimmune Diseases Treated with Immunomodulatory Drugs' by Ansarin Et Al